Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation

Background: Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was eval...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Hiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, Kazumi Nishino, Jun Sakakibara-Konishi, Ryohei Katayama, Shogo Nomura, Shingo Matsumoto, Hibiki Udagawa, Yuji Shibata, Tetsuya Sakai, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Seiji Niho, Koichi Goto
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-01-01
Σειρά:	Cancer Treatment and Research Communications
Θέματα:	EGFR mutation Osimertinib Acquired resistance C797S Brigatinib Panitumumab
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2468294226000146
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!